Last reviewed · How we verify
Avonex
At a glance
| Generic name | Avonex |
|---|---|
| Also known as | Interferon β1A, Interferon beta-1a, Interferon β-1a, interferon beta-1a, BG9418 |
| Sponsor | Biogen |
| Target | Interferon alpha/beta receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Relapsing remitting multiple sclerosis
Common side effects
- Flu-like symptoms (chills, fever, myalgia, asthenia)
- Depression
Serious adverse events
- Anaphylaxis and other allergic reactions
- Depression, Suicide, and Psychotic Disorders
- Hepatic Injury
- Injection Site Reactions Including Necrosis
- Congestive Heart Failure
- Decreased Peripheral Blood Counts
- Thrombotic Microangiopathy
- Pulmonary Arterial Hypertension
- Seizures
- Autoimmune Disorders
Key clinical trials
- An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
- Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (PHASE3)
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis (PHASE3)
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis (PHASE3)
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (PHASE4)
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avonex CI brief — competitive landscape report
- Avonex updates RSS · CI watch RSS
- Biogen portfolio CI